Navigation Links
BioMS Medical to present at BMO Healthcare Conference
Date:7/30/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, July 30 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the BMO Capital Markets "Focus on Healthcare Conference" in New York.

WHEN: Wednesday August 6th at 8:30am (Eastern Time)

WHERE: The Millennium Broadway Hotel, New York

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298 (dirucotide), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 (dirucotide) in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
2. BioMS Medical to present at Jefferies Healthcare Conference
3. BioMS Medical to present at 2008 BIO International Convention
4. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medical announces first quarter 2008 results
6. BioMs Medical to present at TIDES(R) Conference
7. BioMS Medical to present at Rodman and Renshaw Global Healthcare Conference
8. BioMS Medical Provides Update On Pipeline Products
9. BioMS Medical announces conference call and web cast for Annual General Meeting
10. BioMS Medical to Participate in Speciality Panel Session at BioFinance 2008
11. BioMS Medical to present at EQUITIES Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... be valued at $5.6 billion in 2019. It ... 18.1% from 2013 to 2019, and was valued ... research report published by Transparency Market Research. , ... please visit: http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research ...
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 Pittcon ... Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have ... on September 5, 2014. JASIS , Asia’s largest ... 3-5, 2014, in Makuhari Messe, Japan. , The ... Tools for Bioanalysis from Single Molecules to Single Cells” ...
(Date:8/29/2014)... Local veterinarian, Dr. Keith Clement, and his ... to participate in an investigational study of donor stem ... of this study is to determine if a single ... arthritically affected joints can help reduce pain and inflammation ... current investigational study must be older than nine months, ...
(Date:8/29/2014)... 29, 2014 Due to a misstatement posted ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... cell therapy research that might benefit ALS patients. Because ... new stem cell technologies and therapeutic applications, FRC listed ASCTC ... Challenge donors who wish not to support research that ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3
... SAN FRANCISCO, Jan. 10, 2011 Enobia Pharma Inc., ... II study of ENB-0040, a bone targeted enzyme replacement ... serious, rare metabolic bone disorder. The results were presented ... of Enobia, at the 29th Annual J.P. Morgan Healthcare ...
... (Nasdaq: PRXL ) will release Second Quarter Fiscal ... the close of the stock market.  The announcement will be ... the PR Newswire website at www.prnewswire.com . ... 10:00 a.m. EST on Tuesday, February 1, 2011 to discuss ...
... DuPont (NYSE: DD ) has entered ... a global enzyme and specialty food ingredients company, for ... of Danisco net debt.  Upon closing, this transaction would ... with science-intensive innovations that address global challenges in food ...
Cached Biology Technology:Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 2Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 3PAREXEL Announces Date of Second Quarter Fiscal Year 2011 Earnings Release and Conference Call 2DuPont to Acquire Danisco for $6.3 Billion 2DuPont to Acquire Danisco for $6.3 Billion 3DuPont to Acquire Danisco for $6.3 Billion 4
(Date:8/28/2014)... MARC (Maximizing Access to Research Careers) Program has announced ... Human Genetics from October 18 22, 2014 in ... promote the entry of students, post doctorates and scientists ... science community and to encourage the participation of young ... This year MARC conferred 16 awards totaling $29,600., The ...
(Date:8/28/2014)... identified the developmental on-off switch for Streptomyces , ... two-thirds of the world,s naturally derived antibiotic medicines. ... it is possible to manipulate this switch to make ... appearing August 28 in Cell , found that ... and a larger protein called BldD ultimately controls whether ...
(Date:8/28/2014)... measuring and imaging how quickly blood flows in the ... drug abuse affects the brain, which may aid in ... better treatment options for recovering drug addicts. The new ... Brook University in New York, USA and the U.S. ... Optical Society,s (OSA) open-access journal Biomedical Optics ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3
... even a small amount of MDMA, better known as ecstasy, ... study to look at the neurotoxic effects of low doses ... were presented today at the annual meeting of the Radiological ... in blood circulation in some areas of the brain in ...
... India constitute more than one-sixth of the world's ... related to genetic diseases. And with the growth ... and western lifestyles have risen to near-epidemic proportions, ... importance. , In response to this dearth ...
... has yielded new evidence for domesticated horses up to 5,600 ... appear to be the remains of horse corrals beside pit ... by horse manure. The Krasnyi Yar site was inhabited by ... relied heavily on horses for food, tools, and transport. , ...
Cached Biology News:Ecstasy can harm the brains of first-time users 2Researchers make progress in studying genetic traits of India-born populations 2New evidence of early horse domestication 2New evidence of early horse domestication 3
... conserved form of cell suicide, which follows ... component of this process is a cascade ... enzymes participate in a series of reactions ... signals and result in the cleavage of ...
... System provides optimized reagents and protocols for ... genes by insertion of group II introns. ... group II introns and utilizes a simple ... II intron for specific insertion into the ...
Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
Biology Products: